US Launch of GLATOPA

(First Generic of Tevas COPAXONE):

Impact and Analysis

September 2015

Precision Research & Consulting Pvt. Ltd.

www.idatainsights.com

US Launch of GLATOPA (First Generic of Tevas

COPAXONE): Impact and Analysis

1. Executive Summary
2. Introduction

Table of Content (Draft)

REPORT HIGHLIGHTS
An overview of Glatopa (regulatory, marketing, clinical details)
An overview of global multiple sclerosis market

An Overview of Copaxone: Trade name, Class, Target,

Regulatory Status for Multiple Sclerosis, Administration,
Marketing Details

The report analyses the impact of Glatopa launch on industry

competition and answers various key intelligence questions

Clinical Evidence (Glatopa)

The report also analyses opinions of various key stakeholders

on the US launch of Glatopa

3. Sandoz and Momenta Collaboration

Collaboration details
Novartis: First to Market
Impact on Industry Competition
Will Physicians adopt Glatopa?
Will Patients be Happy to Switch Back?
What about other Generic Copaxone Launches?
What about USFDAs Role

A MUST BUY FOR

professional from the pharmaceutical, biotech, medical device and
diagnostics industries with responsibilities or involvement in the following areas:
Competitive Intelligence
Business Intelligence
Information Specialist
Commercial/Customer Insights

Impact on Novartis (Sandoz)/Teva

Strategic Planning

Approval of Glatopa will Sharpen Focus on Tevas M&A

Efforts

Decision Analysis/Decision Support

Potentially Risky Decision for Sandoz and Momenta:

When to Launch Glatopa?
Entry of Glatopa in the MS Market, May not Bring down
the Costs Much

4. Global Multiple Sclerosis Market

5. KOL Comments: Analysis of
Statements from Various KOLs

Market/Marketing Research
Business Analytics
New Product Planning/Development
Forecasting
Librarian
Brand Management/Product Management
Marketing
Business Portfolio Planning
Strategic/Business Analysis
Business Development
Licensing
Technical Analysis
Portfolio Management/Planning
Project Management
Risk Management
Research Planning
Research & Development
Regulatory
Scientist
Legal/Regulatory
Outsourcing
Manufacturing

Precision Research & Consulting Pvt. Ltd.

www.idatainsights.com

US Launch of GLATOPA (First Generic of Tevas

COPAXONE): Impact and Analysis

Order Form

I wish to procure research report US Launch of GLATOPA (First Generic of Tevas COPAXONE): Impact and Analysis priced at Rs
60,000/ 1,000 USD.
I wish to procure research report US Launch of GLATOPA (First Generic of Tevas COPAXONE): Impact and Analysis priced at Rs
54,000 / 950 USD as I am wishing to avail discount.
Note:

1. Additional INR 5000 / 100 USD for Hard Copy printing

2. 10% Discount till August 31st 2015

Name (Block Letters)_______________________________________________________ Designation_______________________

Company_____________________________________________________________________________________________

Mailing Address_________________________________________________________________________________________

Telephone_________________________________________ Mobile_______________________________________________

Fax_________________________________________ E-mail____________________________________________________

Wire Transfer details:

For cheque/demand draft:

Beneficiary: Precision Research and Consulting Pvt. Ltd.

I am enclosing a cheque/demand draft of

Bank Name: ICICI Bank Ltd.

INR/US$:

Bank Account No.: 664305500082

vide cheque/DD no.:

IFSC Code: ICIC0006643

drawn on:

Swift Code: ICICINBBCTS

dated:

Bank Address: J-8, Vikas Puri, New Delhi - 110018 (INDIA)

In favour of:

Contact Details:

Corporate Office:

K Venkat

Precision Research and Consulting Pvt. Ltd.

Tel: +91 - 11 - 45544187, 41630406

502, Vishwadeep Tower, District Centre,

Mobile: +91 - 8527803963

Janak Puri, New Delhi - 110058

venkat@idatainsights.com

Phone - 011 - 45544187

research@idatainsights.com

www.idatainsights.com info@idatainsights.com

www.idatainsights.com